Abstract Drug discovery is guided by theories regarding disease pathogenesis, and biomarkers are the essential analytical tools used to translate those theories into clinical experiments. Biomarkers can be used to expedite clinical trials by permitting selection of the most uniform and responsive patient population, by reporting on target engagement of a particular therapeutic mechanism, and by permitting measurement of biochemical or physiological correlates of disease mechanism with end points that may be more sensitive, immediate, or statistically robust than phenotypic or behavioral changes. Biomarker discovery necessarily begins with an analytically validated assay for an analyte, which is later qualified by demonstrating its utility in some context of disease and therapeutic state. Ultimately, just as with the drug discovery process as a whole, successful biomarker discovery and development depends upon a clear understanding of the disease process. This article reviews the challenges of biomarker discovery with an emphasis on fluid biomarkers in neurodegeneration.
Introduction
Biomarker discovery is an integral component of the drug discovery process. In a well-planned discovery program, biomarker discovery efforts commence early and proceed in parallel with the drug discovery process [1] . Efficacy biomarkers are as necessary for lead optimization and preclinical efficacy studies as they are for clinical studies, and the early incorporation of a biomarker strategy in the drug discovery process allows for adequate exploration of the role of a given analyte in disease pathogenesis, as well as its half-life, distribution, metabolism, and the possible role of post-translational modifications [2] . Biomarkers and therapeutic targets are often identified as components of hallmark pathological lesions, especially in neurodegenerative diseases, and often therapeutic target and biomarker are one and the same analyte. Likewise, genetic predisposition to a disease process informs the selection of therapeutic targets as well as diagnostic and/or stratification biomarkers.
Because biomarkers fill multiple roles in experimental pharmacology, an essential first step in biomarker discovery is to delineate the role a specific biomarker will play in the spectrum of research. The requirements for a diagnostic biomarker, for example, may be very different than those of a biomarker of disease progression or of toxicity. Biomarker applications include diagnosis or assessment of disease susceptibility, patient stratification, therapeutic target engagement, and disease progression or staging, as well as off-target and toxic effects. For a biomarker to have utility it must be informative with respect to one of these applications, and it must have an analytically validated assay that can be reproduced between different studies and different laboratories. The availability of such an assay enables the subsequent qualification of the biomarker, which is the demonstration of a disease-related change in the biomarker levels of an appropriate analyte. The relevance of the biomarker needs to be verified by additional studies, preferably conducted by different laboratories, before clinical validation and commercialization of the biomarker assay may begin (see Fig. 1 ).
The Challenges of Biomarker Discovery
Biomarkers may be identified by virtue of their presence in pathological disease-associated lesions, such as the components of the senile plaques, congophilic angiopathy, and neurofibrillary tangles that are characteristic of Alzheimer's disease (AD) [3] or the Lewy Bodies that are pathognomic for Parkinson's disease (PD [4] ). This is the source of interest in the pathogenic fragment of the amyloid precursor protein (APP), amyloid beta (Aβ), the microtubuleassociated protein (MAPT) tau, and α-synuclein (SNCA), respectively. The association of a biomarker with these lesions carries with it significant face validity; however, this association may be due to secondary processes or epiphenomena, and a functional relationship with disease must always be established.
Alternatively, biomarkers may be identified in a hypothesisfree manner by surveying total proteins present in appropriate samples using proteomic approaches [5] , assessment of global post-translationally modified proteins (eg, phosphoproteomics [6] ) and via prediction from genomics approaches. The global proteomics approach has proven most powerful in the identification of multiple analyte panels (MAPs) of several analytes, which collectively provide a significantly more robust predictive value than any of the constituent analytes provide individually [7] . Expression profiling may yield clues regarding differential expression of genes and perturbations of signaling networks in disease states or in response to drug treatments [8] . Surrogate biomarkers associated with a disease state or a therapeutic effect also may be discovered through unbiased expression profiling. Genome-wide association studies (GWAS) have proven increasingly valuable in linking disease with genotypic variation (eg, the sequence variants associated with genetic risk for PD [9] ). Other promising new genomics approaches include analysis of regulatory micro RNAs (miRNAs) [10•, 11] as well as examination of the genome-wide splice array [8, 12•] .
Biomarker analytes may be restricted to specific compartments, such as the plasma compartment or the cerebrospinal fluid (CSF). This is especially important for most central nervous system (CNS) studies, where the matrix for biochemical biomarkers is often restricted to lumbar or, rarely, ventricular CSF samples, because biomarkers such as tau are often not detectable in plasma serum. There are multiple factors that may impact analyte levels in CSF or other matrices that are independent of disease process, including transport across compartment barriers, such as the bloodbrain barrier (BBB), CSF circulation to point of collection, and analyte stability. Analyte levels also may be responsive to biological activity, such as neuronal activity in the brain, and may exhibit circadian patterns or gender specificity.
Given these complexities, CNS diseases often require a biomarker approach examining a surrogate target tissue. For example, biopsies of peripheral nerve may serve as a surrogate for CNS neuronal pathophysiology. Biopsies of cutaneous nerves [13] , enteric nerves [14] and the nerve supply of salivary glands [15] are being investigated for their utility for the investigation of the intraneuronal pathology that accompanies disease progression in PD. Surrogate biomarkers by definition are a step removed from the site of action and/or desired clinical endpoint, and therefore may carry with them unique qualification concerns [16] .
Analytical Validation
A robust, analytically validated assay is necessary for a clear understanding of an analyte's utility as a biomarker. The analytical validation of an assay is a close examination of the physiochemical properties of the analyte being measured, the analyte's interaction with other assay components, and the inherent platform sensitivity. Validation parameters interrogate an analyte's stability, its interaction Fig. 1 Biomarker discovery and validation pipeline. Biomarkers having a specific application are assessed by assays that have undergone a rigorous analytical validation. Multiple parameters are evaluated according to a method validation plan. The impact of pre-analytical factors is also determined. The analytically validated assay is used to qualify the biomarker in a given disease state. After replication in additional studies in additional laboratories, the assay is optimized and commercialized MOA mechanism of action with matrix components, and the range of its levels in relevant matrices and populations in the context of the robustness of an assay detection technology. Here, we review approaches for soluble biomarkers, using ligandbinding approaches such as enzyme-linked immunosorbent assay (ELISA). Other biomarker modalities such as imaging have their own complex validation challenges [17] , which are beyond the scope of this review, as are the issues confronting the validation of bioanalytical methods for small molecules [18] and large molecule therapeutics [19] . The American Association of Pharmaceutical Scientists (AAPS)/ U.S. Food and Drug Administration (FDA) 3rd Bioanalytical Workshop Best Practices for quantitative bioanalytical methods validation [20] , as well as best practices concerning characterization of assay reagents, standards, quality controls, study samples, and analyte stability have been reported [21] . Recommendations of the European Medicines Agency (EMEA) are available [22] . Recommendations reflecting a pharmaceutical industry perspective emphasize the importance of immunoassay specificity, since the analyte is not typically extracted from matrix before assessment in this type of assay [23] . Others emphasize the importance of parallelism among assay validation parameters [24] . Validation of a clinical diagnostic biomarker and its analytical assays often requires additional criteria such as patient population criteria and clinical reference range
The degree to which an assay is analytically evaluated depends upon the assay's intended use, and will determine the validation methodology employed. It is often the case that a biomarker assay intended only for exploratory use will be minimally validated compared to an assay intended for clinical use. Research Use-Only applications (RUO) are outside the umbrella of guidance provided by such governing bodies as the FDA and EMEA. Therefore, despite the extensive literature on the topic of immunoassay validation schemes, the make-up of the experimental plans used to validate an immunoassay for a given intended use varies greatly between research institutions.
The parameters evaluated during an analytical validation of an assay as well as the AAPS recommended acceptable values have been reported [25] . In general terms, these parameters evaluate proportionality between input levels of analyte and assay signal which, in a typical sandwich ELISA assay, reflect upon the capture capacity and signal/ noise ratio (sensitivity, linearity, reference interval), the interaction of the analyte with matrix components (accuracy/ recovery, dilutional specificity), intra-and interassay precision and drift (influenced by manufacturing factors such as capture antibody coating or conjugation technique, and the robustness of the assay protocol with respect to pipetting technique, washing methods, as well as mixing and incubation time and temperature), and the stability of the analyte, which may relate to an analyte's degradation or aggregation (evaluated in a stability experiment). An assay's reproducibility and face validity (method comparison) are also evaluated (see Table 1 ).
Accuracy is often assessed by simple spike-recovery experiments using a concentrated and well-quantified source of analyte and a pooled matrix to create spikes that span the standard curve range. In general, the final volume of the spike should be no more than 10% of the final total sample volume, and the common acceptance criteria is recovery of 80% to 120% of the nominal value [20] . In cases where the endogenous analyte level is within the limit of quantitation of the assay, the matrix should be analyzed alongside the spiked samples to allow for correction of the measured spike values with that of the measured endogenous analyte value. Ideally, spikes should be at least three times the endogenous analyte level because the formulas used for spike-recovery with endogenous correction are vulnerable to situations in which the spike value is very near the endogenous value. Such experiments are confounded by the existence of matrix proteins that bind to the analyte, and thus, cause underrecovery of analyte.
The complexity of the matrix fluid often complicates a biomarker assay with respect to the nonspecific matrix interference for analyte detection. Poor sensitivity or linear range may be attributable to poor performance of the detection reagents, signal quenching, or other signal interference from the matrix. Many alternative platforms are available for the enhancement of the sensitivity and linear range of protein assays. Among the microplate-based immunochemical assays, options beyond the basic enzyme-conjugated colorimetric or fluorometric assay include electrochemiluminescent assays [26, 27] , solution ELISA [28] , AlphaLISA (PerkinElmer, Waltham, MA) [29] , TR-FRET (time-resolved fluorescence [TRF]/fluorescence resonance energy transfer), dendrimers [30] , and proximity ligation assays [31] . There are several studies comparing the relative utilities of various assay platforms [27, 28, 32] ; however, it has been reported that it is difficult to predict the best platform for a given application, and that the best platform often needs to be selected empirically [33] . Certain detection modalities such as luminescence and TRF perform quite differently depending upon the instrumentation used to analyze the signal, and therefore, assays based upon them can exhibit large differences in apparent sensitivity between labs.
Because the interaction of matrix components with the analyte or with assay components can cause significant problems with an assay, a number of analytical strategies have been employed to address this challenge. Sample dilution may reduce nonspecific matrix interference for biomarker detection, but the analytical sensitivity of a biomarker assay and the low endogenous abundance of a biomarker in biological fluids may preclude this strategy for reduction of matrix interference. In contrast, if analyte levels are exceedingly low, samples may be concentrated or multiple sample volumes may be loaded to a solid phase assay in an effort to saturate capture reagents with analyte from a larger total sample volume. Often, detergents, chelators, or chaotropes are employed to reduce nonspecific protein-protein interactions that may contribute to matrix effects. In utilizing such techniques, the investigator should remain cognizant of the fact that antibody-analyte interaction is also a protein-protein interaction susceptible to the same treatments, even though their interaction (binding) is generally of greater affinity. An additional confounder for immunoassays employed in drug research is interference from drug molecules that bind to the target analyte, and thus, potentially obscure important epitopes required for assay antibody binding. The standard methodology to reduce this binding (eg, acidification of the sample) also can suppress assay antibody binding, or increase matrix interference from denatured matrix proteins. Binding equilibrium experiments also must be performed to show that the capture antibodyanalyte complex is able to reach a steady state under the lower pH conditions during the allotted incubation time.
Pre-analytical factors may contribute to both matrix effects and analyte stability, and appropriate sample collection protocols need to be delineated, including need for anticoagulants/ chelators, addition of enzyme inhibitors, collection tube material (eg, plastic, glass), sample preparation (centrifugation, denaturation), freeze-thaw cycle, and storage conditions. Disease state and physical condition may impact samples as well. It is important that clear instructions be given to surgical staff when collecting samples from patients or research animals. Training procedures must be followed to ensure consistency in sample collection (eg, collection protocol, sample containers, sample preparation and storage). The maximum dilution allowable in a beyond the MRD is set at the last dilution factor in a series of dilutions at which the %RE is ≤20% The preparation, handling, and quality control of standard reference material used in standard curves are critical to the successful execution of an assay. Biological control standard materials may be hydrophobic or have a propensity to aggregate, precipitate, or degrade. Denaturation, oxidation, and reduction of protein standards used in immunochemical assays of biomarkers are particularly problematic, and can easily led to failure of an analytical validation or sample analysis. It is of utmost importance for a biomarker assay meant for large-scale use that the standard and control material be formulated in such a way that the materials are amenable for assay scale-up, stable for long periods of time, and exhibit excellent lot-to-lot consistency with respect to the signal obtained from the intended assay. If standard material cannot be made in large, stable, reproducible batches, extreme caution must be exercised when comparing and interpreting biomarker data obtained when different batches of control standard materials are used. This caveat is also applicable to other rare assay components such as the assay antibodies, enzymes, and other signal detection reagents that are part of the biomarker detection assay. Quality control of the control standards may encompass, but is not limited to, molecular characterization (eg, proteins and small molecule biomarker standards), activity analysis (eg, enzymatic activity assay standards), or other functional analysis (eg, standards for cell-based in vitro activity assays). Reference control standards of assays must be analyzed and quantified by an analysis independent of the biomarker assay in analytical validation or sample analysis. Manufacturers of such assays should ideally align future assay production lots to the results obtained by a master lot. Assay comparison should minimally reveal congruence in relative values of samples, if not agreement of absolute calculated values. Assays that require standard material are beholden to other orthogonal technologies that can accurately quantify the standard material before it is used in an assay. Absence of techniques that can quantify the standard material before assay implementation may limit the utility of such a biomarker assay to determination of relative values (eg, antibody titer assay). The World Health Organization (WHO) can be a source of reference standard proteins that can be used to compare the results of different immunoassays. Difference in absolute values may result from difference in antibody affinities or epitopes, differences in sensitivities of assay platforms (if applicable), or handling of reagent components critical to the creation of the assay standard curve.
Examples of Analytical Validation Challenges
Some of the most intensely studied CSF analytes are illustrative of many of the issues encountered during the analytical validation of a biomarker. Here, we will review efforts to validate assays for the AD-associated Aβ 42 , tau (total tau [t-tau]) and phospho-tau (p-tau), use of which has been recommended for AD clinical trials [34] , as well as the PD-associated protein SNCA (see Table 2 ).
Aβ is a secreted peptide with multiple genetic linkages to AD both regarding its precursor protein (APP) and components of the enzyme complexes responsible for generation of Aβ from APP (the presenilins, PS1, and PS2) [3] . Aβ is also widely regarded as forming a pathogenic oligomeric species in AD; thus, Aβ is implicated functionally and genetically in AD pathogenesis, and is regarded as a therapeutic target, as well as a diagnostic biomarker and biomarker of disease progression. Several biomarker assays using multiple different platforms have been developed to interrogate the ability of a test therapeutic compound to cause ostensibly therapeutic reductions in Aβ or Aβ oligomers [35, 36] .
However, Aβ is a remarkably challenging analyte. Cterminal heterogeneity results in peptides ranging from 38 to 43 amino acids in length. The 40-amino acid peptide is most abundant, while the longer peptides (eg, Aβ 42 ), which are more hydrophobic and more prone to aggregation, are considered more toxic. Amino-terminal truncations and pyroglutamate modifications also occur and have been implicated in the disease process [37] . Aggregation results in the formation of insoluble amyloid fibrils as well as soluble oligomers, which are reported to be central to pathogenesis, although there is controversy regarding the specific species of oligomer involved. The poor solubility of the analyte and its propensity to aggregate necessitate very specific preanalytical handling [38, 39] . The secretion of Aβ is activity dependent, shows extensive fluctuations throughout the day [40] , and it is actively transported across the BBB, being a substrate of transporters such as P-glycoprotein (Pgp) [41] and low density lipoprotein receptor-related protein 1 (LRP-1) [42, 43] . Indeed, decreased clearance across the BBB has been implicated in disease pathogenesis [44] . While brain Aβ 42 load increases with disease, Aβ 42 measured in CSF decreases significantly as early as 10 years before onset of cognitive impairment [45] . However, turnover of Aβ in humans is rapid [46] , and stable isotope labeling [47] has been used to confirm the inhibition of Aβ generation by compounds such as the γ-secretase inhibitor LY-450139 (Semagacestat), demonstrating that pools of Aβ are dynamic and show measurable changes in response to attempts at therapeutic intervention.
In the case of LY-450139, Aβ was an effective biomarker of target engagement, by demonstrating, as predicted, a compound-dependent reduction of Aβ generation and secretion into the CSF. However, a far more complex question is whether pharmacological manipulation of this biomarker can be correlated with changes in the most relevant trial end point, cognition. In this case, despite the close genetic and functional associations of Aβ with AD, and despite the fact that this compound effectively reduced generation of this biomarker and therapeutic target, LY-450139 failed in phase 3 because it caused deterioration of cognitive function, precisely the opposite effect as was predicted [48] .
MAPT contrasts in many ways with Aβ. Unlike Aβ, tau has not been genetically associated with AD (it has been associated with PD [4] as well as with frontotemporal lobar dementia [49] ), although tau pathology is a hallmark of AD. Also, unlike Aβ, tau is primarily an intracellular protein, although recent studies demonstrate active secretion [50] of the protein. Another report confirms the presence of extracellular tau in the absence of neurodegeneration, but finds no correlation between levels of tau in brain interstitial fluid and in CSF [51] . Tau is subject to extensive post-translational modification, the most prominent being proteolytic processing, nitration, and phosphorylation [52, 53] . It is not clear whether disease-related changes in t-tau levels are due to augmented secretion or exocytosis of the protein through an active process, or due to a passive release from dead and dying neurons. Nor is it clear whether the tau fragments in CSF from AD patients are different those found in CSF from non-AD patients. Finally, the phosphorylated form of tau most often measured, p181-tau, may not represent the phosphorylation site that is most predictive of disease progression, or informative of disease state, but it is measured because of convention, and availability of an assay.
Therefore, these biomarkers, although linked to the disease by pathology, are subject to a multitude of posttranslational modifications, including truncations, phosphorylation, and aggregation, presenting a multiplicity of potential epitopes to follow, any of which might have more disease relevance than those epitopes currently being measured. These biomarkers are actively transported in ways that may alter measured levels of analyte, but there is no clear understanding of the link, if any, between those transport functions and disease. The value of these biomarkers would be questionable even if the analytical assays were unimpeachable, which they are not. The most commonly used assays are the Innotest assays (Innogenetics, Gent., Belgium) [54] . The Innotest assay for total tau interrogates only 15% of a highly variable molecule, while the p181 epitope, measured in the phospho-tau assay is only one of many phosphoepitopes for this protein, and the rationale for measuring it rather than other phosphoepitopes is controversial. High interlaboratory variability [55, 56] calls into question the reproducibility of studies using these assays and resulted in a call for standardization of pre-analytical and analytical methods [57] . Meanwhile a method comparison of the two versions of the Innotest assay (ELISA, and Aβ amyloid beta; oAβ oligomeric amyloid beta; t-tau total tau; p181-tau tau phosphorylated at threonine 181; GWAS genome-wide association studies; miRNA micro RNA; PET positron emission tomography; FDG-PET fluorodeoxyglucose positron emission tomography; apoE4 apolipoprotein E4; PS presenilin; APP amyloid precursor protein; TOMM40 translocase of outer mitochondrial membrane 40; SNCA α-synuclein; oSNCA oligomeric α-synuclein; pSNCA phosphorylated α-synuclein; DAT-SPECT dopamine transporter-single photon emission computed tomography; VMAT vesicular monoamine transporter; LRRK2 leucine rich repeat kinase 2; PINK1 phosphatase and tensin homolog (PTEN)-induced putative kinase-1; UCHL1 ubiquitin C-terminal hydrolase L1; GBA glucocerebrosidase * Examples of fluid, genomic, and imaging biomarkers diagnostic biomarkers of disease progression used for diagnosis assessment of disease progression, patient stratification or assessment of disease susceptibility are provided
Luminex-based multiplex assays) resulted in widely divergent absolute analyte values [54] . Yet, reports claim utility for these assays, but only "when [an] astringent analytical protocol is used" [58] . Recent diagnostic recommendations from the National Institute on Aging (NIA) and the Alzheimer's Association workgroup for mild cognitive impairment state that "Considerable work is needed to validate the criteria that use biomarkers and to standardize biomarker analysis" [59] , while recommendations regarding diagnosis of AD state that, although biomarkers might enhance specificity of the diagnosis, clinical criteria would continue as the "cornerstone of the diagnosis" [60] . A recent EMEA qualification opinion acknowledges issues regarding the reliability and complexity of the measurement methods, suggests that standardization may be an important part of resolving those issues, and while expressing concern that a positive signal from the measures of these CSF analytes is "not well defined," concludes that a positive profile of these analytes is "predictive for the evaluation of the ADdementia type" [61] . Importantly, there also have been calls to better exploit the potential of genetics [62••] and proteomics [63] , and to look beyond Aβ and tau for potential "second hits" that might improve our abilities to predict disease progression. Nevertheless, a recent failure to confirm a plasma biomarker panel for AD is a sobering reminder of the difficulties inherent in these efforts [64] . SNCA has extensive face validity as a biomarker for PD, with both point mutations and duplication/triplication of the wild-type SNCA locus causing autosomal dominant disease [4] , while SNCA deposits in the form of Lewy bodies and Lewy neurites are hallmark pathologies [65] . Just as with tau, SNCA is an intracellular protein whose exocytosis has recently been reported [66, 67] . Thus, levels in CSF may be influenced by altered active exocytosis and passive release from degenerating neurons. CSF levels of SNCA decline with disease progression, ostensibly due to aggregation of protein [68, 69] . Both SNCA and tau feature prominently in the Manhattan plots of GWAS studies for PD [70] ; however, CSF tau levels are relatively unremarkable in PD and tau does not contribute appreciably to pathology in this disease. Again, similar to tau, SNCA exists in multiple isoforms [71] [72] [73] , is subject to post-translational modifications, which have been implicated in pathogenesis and which may signal acceleration of the disease process, such as phosphorylation and nitration [74] [75] [76] [77] [78] [79] [80] [81] and truncations [82] [83] [84] , while the most commonly employed assays are agnostic to the presence of these modifications. Nevertheless, there has been a call to qualify SNCA as a biomarker for PD [69] . In contrast to AD biomarker research, which is well established, research in the field of PD biomarkers is both less driven by established convention and less developed than that of AD biomarkers. Currently, there are significant ongoing efforts to address PD biomarker development in a coherent and comprehensive manner through the efforts of the Parkinson's Progression Markers Initiative (PPMI) as well as other nonprofit and precompetitive initiatives.
Clinical Validation and Regulatory Challenges
Biomarker discovery and development is a challenging and protracted process. Between 1995 and 2010, the FDAapproved biomarker assays at a rate of fewer than two assays per year [85] . Because primary research continues unabated during the lengthy process of biomarker validation, important post-translational modifications or completely new and potentially more relevant candidate biomarkers may emerge in the interim. Among the difficulties in validating clinical biomarkers are disease heterogeneity, clinical diagnostic accuracy, and the possibility of the coexistence of multiple disease processes [86] .
Clinical validation of biomarkers typically occurs in parallel with the development of a drug targeting a particular mechanism of action. Alternatively, biomarkers may be developed to assess the safety or efficacy of several drugs having a common efficacy or toxicity mechanism. The latter instance has led to the FDA Biomarker Qualification Process [87] for such critical end points as kidney toxicity [88, 89] subsequent to the launch of the FDA Critical Path Initiative (CPath [90] ). Efforts to enhance precompetitive biomarker development in neurological diseases led CPath, the Brookings Institute, the FDA, EMEA, the NIA, the National Institute of Neurological Disorders and Stroke (NINDS) and multiple industry and academic representatives to form the Coalition Against Major Diseases (CAMD [91] ) to develop disease progression models, help identify biomarkers, and help drive collaboration and consensus among investigators and regulatory agencies.
Just as with preclinical biomarkers, the initial step in the qualification of a clinical biomarker remains the context of use, answering the question, "what critical decisions in drug development and the regulatory review will be addressed by this biomarker [92] ?" This provides the basis for a gap analysis to drive acquisition of appropriate data sets necessary to support the proposed context of use. Yet, the complexity and uncertainty of these efforts are enormous. Broich and colleagues [93] point out that a plausible hypothesis in basic science is sometimes disproved in the clinic. For example, one would assume that brain atrophy would be positively correlated with progression of dementia, while in the AN1792 Aβ vaccine trial, brain hippocampal volumes decreased in those patients with clinical improvement. FDA review of biomarkers considers the potential risk of such incorrect results (false negative, false positive results) in determining the overall risk assessment of a diagnostic assay: a higher risk assay would be classified as class III and would require a premarket application (PMA), while most would be categorized as class II requiring a 510(k) submission. The FDA process for a proteinbased biomarker is outlined in a mock presubmission reported by Regnier et al. [94] .
Conclusions
Biomarker discovery and validation are integral components of the drug discovery process, and require clear definition of intended use and rigorous analytical assay validation. While regulatory approval of clinical biomarkers has been slow, a rational approach towards accelerating diagnostics development is currently emerging [95] . This is driven in part by precompetitive consortia and by increasing clarity regarding requirements from regulatory agencies [96] , including specific recommendations regarding biomarker qualification [97] . New methods and strategies for biomarker discovery have been reported [10•, 12•, 62 ••] and may aid in the development of critically needed therapies.
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